Oncocyte Enters $2B Market With Transplant Rejection Monitoring Test

Oncocyte Corporation OCX completed the development and clinical validation of the Laboratory Test for its newly-branded VitaGraft Transplant Monitoring tests for Liver and Kidney, entering a $2 billion US market.
The company also opened an Early Adopter Program (EAP), giving access to transplant centers before a potential CMS coverage decision and full commercial launch.
VitaGraft has been well-studied across Kidney, Liver, and Heart with over 20 peer-reviewed publications from studies in over 600 patients and over 5,000 samples.
It is a simple and non-invasive blood test that has been shown to accurately rule-out rejection or injury following transplant with negative predictive values above 97%, helping avoid around 30% of unnecessary biopsies.
Furthermore, the test can assist physicians in optimizing the dosing of immunosuppressive drugs to minimize drug-related side effects and toxicity.
Price Action: OCX shares are up 1.20% at $0.87 during the market session on the last check Wednesday.